# Enlivex Therapeutics (ENLV) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ENLV
## Company Profile
- Ticker: ENLV
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Israel and listed in the U
- Tags: Immunotherapy
## Stock Data
- Close: 0.362 USD
- Market cap: 204867310.5276 USD
- Last updated: 2026-10-05
## Business Overview
Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.
## Why The Stock Is Moving

As of Oct 5, 2026, ENLV closed down 6.53% at $0.3620. No new same-company headline was identified in the current news window.

## Geographic Base

Enlivex is headquartered in Israel and listed in the U.S. market. It sits in small-cap immunology biotechnology.

## Business Model

The company depends on translational validation, early clinical progress, and capital support. Investors typically watch proof-of-concept data and whether the platform can create durable value.

## Landscape Position

Enlivex occupies a niche innate-immunity position within biotech. The stock is driven by whether macrophage reprogramming can become a meaningful therapeutic strategy.

## Future Catalysts

- Enlivex’s catalysts are Allocetra and its osteoarthritis / immunology programs, along with any update that clarifies whether the platform still has a viable path. The company remains data-sensitive.

## Recent News
- 2026-09-22 13:00 EST — [Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens](https://biopharmsignal.com/news/ENLV/enlivex-announces-termination-of-previously-announced-financing-payable-in-rain--d017910b) — Source: Enlivex Therapeutics
- 2026-07-30 13:00 EST — [Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-rain-trading-volume-reaches-860mm-622-month-ov-4d007b06) — Source: Enlivex Therapeutics
- 2026-07-29 13:00 EST — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-e5852b02) — Source: Enlivex Therapeutics
- 2026-07-28 13:00 EST — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-65760383) — Source: Enlivex Therapeutics
- 2026-07-20 13:00 EST — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9) — Source: Enlivex Therapeutics